Alumis Inc.ALMS

ALUMIS INC. (ALMS) kicked off 2026 by setting $93.1 million on fire. The biotech’s Q1 numbers, filed May 14, reveal a company where revenue ($1.7 million) is barely enough to cover a mid-tier executive’s bonus, while R&D expenses ($81.5 million) suggest it’s either curing cancer or building a very expensive treehouse. Cash reserves sits at $63.9 million, but operating cash flow tells the real story: a -$87.1 million outflow, meaning ALMS is burning through its savings faster than a crypto bro in 2021.

What does ALMS actually do? The 10-Q mentions ‘development programs’ and a customer concentration risk so extreme that a single client spending $170,000 (10% of $1.7 million) could be tagged as ‘significant.’ This isn’t a company-it’s a science fair project with a Bloomberg terminal. The recent flurry of Form 4 filings (July 2 saw three separate insider transactions) suggests executives are either confident or clearing out the pantry before winter.

The numbers don’t lie, but they do perform stand-up. ALMS’s balance sheet claims $671.6 million in assets, yet liabilities are only $104.6 million. The gap? Mostly goodwill and intangible assets-accounting euphemisms for ‘we spent a lot on stuff that might not work.’ With a diluted loss per share of $0.74 and 125.1 million shares outstanding, this stock’s only guarantee is math: more shares mean more dilution, and more dilution means… well, you can guess where that ends.

Chart-watchers have little to cling to. No major news or guidance updates have surfaced since the Q1 filing, and the 144 filing on July 6 (a routine securities sale notice) did nothing to shake the tree. If ALMS has a catalyst, it’s hiding behind a wall of negative cash flow and R&D bets that could make a Vegas roulette wheel look conservative.